Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 17 Jun 22 RW Registration withdrawal request
- 23 May 22 424B3 Prospectus supplement
- 10 May 22 EFFECT Notice of effectiveness
- 9 May 22 424B3 Prospectus supplement
-
9 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Mar 22 S-4 Registration of securities issued in business combination transactions
BIOT similar filings
Filing view
External links
Exhibit 23.2
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated March 15, 2022, with respect to the consolidated financial statements of Blade Therapeutics, Inc. included in the proxy statement/prospectus of Biotech Acquisition Company that is made a part of Amendment No. 4 to the Registration Statement (Form S-4 No. 333-263577) and Prospectus of Biotech Acquisition Company for the registration of its common stock.
/s/ Ernst & Young LLP
Redwood City, California
May 6, 2022